Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Net Margin came in at 12.74% in Q2 2026, up 2208.0% YoY from 0.55% in Q2 2025, and down 27.8% on a QoQ basis from 17.65% in Q1 2026.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Net Margin data on file, last reported at 12.74% in Q2 2026.
- Quarterly Net Margin rose 2208.0% year-over-year to 12.74% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 16.13% (up 3119.0% YoY) and the FY2025 annual result came in at 8.45%, up 2082.0% from the prior year.
- Net Margin eased to 12.74% in Q2 2026, from 17.65% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 23.43% in Q3 2025 to a low of 153.58% in Q3 2022.
- A 5-year average of 36.83% and a median of 18.2% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin surged 17327 bps — and 2025, when it sank 4750 bps.
- Tracing ALNY's Net Margin over 5 years: stood at 61.93% in 2022, then soared by 49 bps to 31.35% in 2023, then soared by 55 bps to 14.12% in 2024, then soared by 172 bps to 10.17% in 2025, then increased by 25 bps to 12.74% in 2026.
- The last three Net Margin figures came in at 12.74% (Q2 2026), 17.65% (Q1 2026), and 10.17% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 34.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.74% |
| Mar 31, 2026 | 17.65% |
| Dec 31, 2025 | 10.17% |
| Sep 30, 2025 | 23.43% |
| Jun 30, 2025 | -9.34% |
| Mar 31, 2025 | -60.84% |
| Dec 31, 2024 | -14.12% |
| Sep 30, 2024 | -22.27% |
| Jun 30, 2024 | -2.56% |
| Mar 31, 2024 | -13.34% |
| Dec 31, 2023 | -31.35% |
| Sep 30, 2023 | 19.69% |
| Jun 30, 2023 | -86.59% |
| Mar 31, 2023 | -54.53% |
| Dec 31, 2022 | -61.93% |
| Sep 30, 2022 | -153.58% |
| Jun 30, 2022 | -123.39% |
| Mar 31, 2022 | -112.70% |
| Dec 31, 2021 | -99.97% |
| Sep 30, 2021 | -109.00% |